Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor

European Journal of Clinical Investigation

Volumn 42, Issue 10, 2012, Pages 1061-1067

  Nguyen, Jennifer P ^a   Frost, Chelsea D ^b   Lane, Meghan L ^b   Skelton Iv, William P ^c   Skelton, Michelle ^b   Vesely, David L ^b  

^a WICHITA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Atrial natriuretic peptide; Kaliuretic peptide; Long acting natriuretic peptide; Vascular endothelial growth factor (VEGF); VEGFR2 KDR Flk 1 receptor; Vessel dilator

Indexed keywords

ATRIAL NATRIURETIC FACTOR; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; SMALL CELL LUNG CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84866275052     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02695.x     Document Type: Article

References (33)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
2. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
3. Hoeben A, Landuyt B, Highley MS, Wilders H, Van Oosterom AT, DeBruijn EA. Vascular endothelium growth factor. Pharmacol Rev 2004;56:549-80.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;295:1182-6.
5. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
6. Doanes AM, Hegland DD, Sethi R, Kovesdi I, Bruder JT, Finkel T. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 1999;255:545-8.
7. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001;276:49289-98.
8. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005;9:777-94.
9. Wang K, Jiang YZ, Chen DB, Zheng J. Hypoxia enhances FGF-2 and VEGF stimulated human placental artery endothelial cell proliferation: roles of MEK-1/2/ERK-1/2 and PI3K/AKT1 Pathways. Placenta 2009;30:1045-51.
10. Gupta I, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999;247:495-504.
11. Breslin JW, Pappas PJ, Cerveira JJ, Hobson RW II, Duran WN. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol 2003;284:H92-100.
12. Vesely DL. Natriuretic hormones. In: Alpern RJ, Herbert SC, editors. Seldin and Giebisch's, The Kidney: physiology and Pathophysiology. 4th edition. London, UK: Elsevier Inc, 2007:947-77.
13. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000;5(Suppl 1):S3-10.
14. Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr, Vesely DL. Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest 2008;38:562-70.
15. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL et al. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 2007;21:445-52.
16. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr. Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 2007;21:973-8.
17. Sun Y, Eichelbaum EJ, Skelton WP IV, Lenz A, Regales N, Wang H et al. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009;29:971-5.
18. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP IV, Wang H, Vesely DL. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009;29:1889-93.
19. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007;27:1387-92.
20. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007;27:3813-8.
21. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 2006;26:3217-22.
22. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 2006;26:4143-8.
23. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanism of action. Exp Cell Res 2006;312:594-607.
24. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
25. Couzin-Frankel J, Ogale Y. Once on 'fast track' Avastin now derailed. Science 2011;333:143-4.
26. Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for the primary care physician. Cardiol Res Pract 2011; 2011:816897, doi: 10.4061/2011/816897, Published online May 10.
27. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994;90:1129-40.
28. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998;98:323-9.
29. Clark LC, Farghaly H, Saba SR, Vesely DL. Amelioration with vessel dilator of acute tubular necrosis and renal failure established for two days. Am J Physiol 2000;278:H1555-64.
30. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol 2003;285:F167-77.
31. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Saszuki T et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
32. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marmé D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-9.
33. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cellular Signaling 2007;19:2003-12.